ProCE Banner Activity

BCMA x CD3 Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma: Update of a Phase I First-in-Human Study

Slideset Download
Conference Coverage
Investigational BCMA-targeted bispecific antibody ABBV-383 continues to be well tolerated with promising activity in patients with R/R MM.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation